FDA
Articles tagged with “FDA”
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
NRx FDA Review: Preservative-Free Ketamine Moves Forward
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what the formulation difference means for low-dose patients.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.
NRx Moves Closer to FDA-Approved Preservative-Free Ketamine
NRx Pharmaceuticals signals FDA review progress on its preservative-free ketamine application. What this means for patients and clinicians in 2026.
Psychedelics Executive Order: What It Means for Ketamine
A new executive order targets psychedelic medicine access. Here's what the policy shift means for low-dose ketamine patients and providers in 2026.
Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines
Regulatory guide for marketing at-home ketamine therapy and esketamine services, covering FDA rules, DEA requirements, and state telemedicine laws.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.